Please wait a minute...

中国生物工程杂志

CHINA BIOTECHNOLOGY
中国生物工程杂志  2015, Vol. 35 Issue (10): 13-19    DOI: 10.13523/j.cb.20151002
研究报告     
MicroRNA-124对人宫颈癌的抑制作用及机制研究
辛婧, 徐银胜, 张芳, 盛望
北京工业大学生物工程与生命科学学院 北京 100124
The Function and Mechanism of MicroRNA-124 in Human Cervical Cancer
XIN Jing, XU Yin-sheng, ZHANG Fang, SHENG Wang
College of life Science and Bio-engineering, Beijing University of Technology, Beijing 100124, China
 全文: PDF(1306 KB)   HTML
摘要:

宫颈癌的发病率在女性恶性肿瘤中占第二位。miR-124的表达在宫颈癌组织中显著下调。目前,发现在宫颈癌细胞中高表达miR-124可显著抑制宫颈癌细胞的生长、迁移与侵袭能力。此外,miR-124在宫颈癌细胞中的高表达还可显著抑制Cdcp1 基因的表达。Luciferase实验结果表明Cdcp1 是miR-124的直接下游靶标基因。在转染miR-124的宫颈癌细胞中高表达CDCP1蛋白可抵消由于miR-124引起的肿瘤抑制作用。这对揭示microRNA在宫颈癌发生、发展中的作用机制及基于microRNA的宫颈癌临床治疗具有一定的潜在意义。

关键词: 宫颈癌CDCP1microRNA-124    
Abstract:

Cervical cancer is the second most common malignant tumor in women around the world. The expression of miR-124 is significantly down-regulated in cervical cancer. The results showed that exogenous expression of miR-124 could remarkably suppress the proliferation and migration of cervical cancer cells. Luciferase analysis showed that CUB domain containing protein 1 gene (Cdcp1) is a direct down-stream target of miR-124 and restoration of CDCP1 counteracted the tumor suppressive effects of miR-124. The results have a great potential for not only the understanding of the relationship between miRNA and cervical cancer, but also microRNA-based anti-cervical cancer therapy.

Key words: CDCP1    Cervical cancer    microRNA-124
收稿日期: 2015-04-28 出版日期: 2015-10-25
ZTFLH:  Q74  
基金资助:

国家自然科学基金资助项目(31440059)

通讯作者: 盛望     E-mail: shengwang@bjut.edu.cn
服务  
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章  

引用本文:

辛婧, 徐银胜, 张芳, 盛望. MicroRNA-124对人宫颈癌的抑制作用及机制研究[J]. 中国生物工程杂志, 2015, 35(10): 13-19.

XIN Jing, XU Yin-sheng, ZHANG Fang, SHENG Wang. The Function and Mechanism of MicroRNA-124 in Human Cervical Cancer. China Biotechnology, 2015, 35(10): 13-19.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20151002        https://manu60.magtech.com.cn/biotech/CN/Y2015/V35/I10/13

[1] Walboomers J M, Jacobs M V, Manos M M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology, 1999, 189(1): 12-19.
[2] Pisani P, Bray F, Parkin D M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. International Journal of Cancer Journal International du Cancer, 2002, 97(1): 72-81.
[3] Zhang W, Jiang Y, Yu Q, et al. EGFR promoter methylation, EGFR mutation, and HPV infection in Chinese cervical squamous cell carcinoma. Applied immunohistochemistry & molecular morphology : AIMM/official publication of the Society for Applied Immunohistochemistry, 2015,in pvess.
[4] Bartel D P. MicroRNAs: target recognition and regulatory functions. Cell, 2009, 136(2): 215-233.
[5] Kusenda B, Mraz M, Mayer J, et al. MicroRNA biogenesis, functionality and cancer relevance. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2006, 150(2): 205-215.
[6] Zhang B H, Pan X P, Cobb G P, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol, 2007, 302(1): 1-12.
[7] Lee J W, Choi C H, Choi J J, et al. Altered MicroRNA expression in cervical carcinomas. Clinical Cancer Research, 2008, 14(9): 2535-2542.
[8] Wang X H, Tang S, Le S Y, et al. Aberrant expression of oncogenic and tumor-suppressive MicroRNAs in cervical cancer is required for cancer cell growth. PLoS One, 2008, 3(7): 11.
[9] Shen S N, Wang L F, Jia Y F, et al. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cance. Diagn Pathol, 2013, 8(69).
[10] Li Y, Wang F, Xu J, et al. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV-related target genes for miR-29. The Journal of Pathology, 2011, 224(4): 484-495.
[11] Wilting S M, Van Boerdonk R A, Henken F E, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Molecular Cancer, 2010, 9(167).
[12] Tian Q F, Li Y, Wang F F, et al. MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women. JNCI-J Natl Cancer Inst, 2014, 106(9): 8.
[13] Peng X H, Huang H R, Lu J, et al. MiR-124 suppresses tumor growth and metastasis by targeting Foxq1 in nasopharyngeal carcinoma. Molecular Cancer, 2014, 13(186).
[14] Hu C B, Li Q L, Hu J F, et al. miR-124 inhibits growth and invasion of gastric cancer by targeting ROCK1. Asian Pacific Journal of Cancer Prevention : APJCP, 2014, 15(16): 6543-6546.
[15] Shi X B, Xue L, Ma A H, et al. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene, 2013, 32(35): 4130-4138.
[16] Sun Y, Ai X, Shen S, et al. NF-kappaB-mediated miR-124 suppresses metastasis of non-small-cell lung cancer by targeting MYO10. Oncotarget, 2015, 6(10):8244-8254.
[17] Zhang Y, Zheng L, Huang J, et al. MiR-124 Radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS One, 2014, 9(4): e93917.
[18] Hooper J D, Zijlstra A, Aimes R T, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene, 2003, 22(12): 1783-1794.
[19] Yang L, Nyalwidhe J O, Guo S, et al. Targeted identification of metastasis-associated cell-surface sialoglycoproteins in prostate cancer. Molecular & Cellular Proteomic, 2011, 10(6): M110.007294.
[20] Miyazawa Y, Uekita T, Hiraoka N, et al. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Research, 2010, 70(12): 5136-5146.
[21] Scherl-Mostageer M, Sommergruber W, Abseher R, et al. Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene, 2001, 20(32): 4402-4408.
[22] Perry S E, Robinson P, Melcher A, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Letters, 2007, 581(6): 1137-1142.
[23] Uekita T, Tanaka M, Takigahira M, et al. CUB-domain-containing protein 1 regulates peritoneal dissemination of gastric scirrhous carcinoma. The American Journal of Pathology, 2008, 172(6): 1729-1739.
[24] Ikeda J, Oda T, Inoue M, et al. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Science, 2009, 100(3): 429-433.
[25] Awakura Y, Nakamura E, Takahashi T, et al. Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma. Journal of Cancer Research and Clinical Oncology, 2008, 134(12): 1363-1369.
[26] Bhatt A S, Erdjument-Bromage H, Tempst P, et al. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene, 2005, 24(34): 5333-5343.
[27] Benes C H, Poulogiannis G, Cantley L C, et al. The SRC-associated protein CUB Domain-containing protein-1 regulates adhesion and motility. Oncogene, 2012, 31(5): 653-663.

[1] 唐敏,万群,孙恃雷,胡静,孙子久,方玉婷,张彦. Hsa-miR-5195-3p对人宫颈癌细胞SiHa增殖、迁移与侵袭的影响 *[J]. 中国生物工程杂志, 2020, 40(4): 17-24.
[2] 冯雪娇,侯海龙,喻琼,王俊姝. 我国宫颈癌疫苗市场分析及对策研究*[J]. 中国生物工程杂志, 2020, 40(11): 96-101.
[3] 李爱芳, 谷月, 李雪茹, 孙晖, 查何, 谢佳卿, 赵佳丽, 周兰. 促宫颈癌细胞增殖、迁移及其可能机制研究[J]. 中国生物工程杂志, 2017, 37(2): 8-14.
[4] 安龙飞, 金龙, 孙凤亮, 李凯, 闫成智, 秦钧, 张普民, 吴琛, 陈欢. 应用蛋白质组学筛选宫颈癌患者尿液中的肿瘤标志物[J]. 中国生物工程杂志, 2016, 36(9): 1-10.
[5] 宋敬东,王健伟,韩金祥,洪涛. 人乳头瘤病毒疫苗的研究进展[J]. 中国生物工程杂志, 2007, 27(4): 104-109.
[6] 王小兵,李茉,刘毅,田海梅,刘朝阳,李艳芬,曹冬艳,粱智,程冬婉,邵长君,张伟. HPV16+治疗性无佐剂蛋白疫苗—HPV16Z- Hsp65-E6/E7的构建、表达及纯化工艺研究[J]. 中国生物工程杂志, 2006, 26(12): 40-44.